In what clinical situations do you switch to Vyalev in patients with Parkinson's disease?  

Vyalev (foscarbidopa/foslevodopa) administered by subcutaneous infusion with an external battery-operated pump, was recently FDA-approved. Conceptually, it offers the prospect of continuous levodopa administration which should improve dyskinesia and motor fluctuations. Skin reactions can be problema...

Agree with the above, which provides general rationale for considering the SQ levodopa. This medication was only just approved a few months ago and few people are on it at this point. In real-world practice, most patients who meet criteria for foslevodopa would also be candidates for deep brain stim...